A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy-Reference-Cited by-同舟云学术

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

Published:2002-03 Issue:4 Volume:16 Page:579-588
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

Cohen Calvin J.,Hunt Susan,Sension Michael,Farthing Charles,Conant Marcus,Jacobson Susan,Nadler Jeffrey,Verbiest Werner,Hertogs Kurt,Ames Michael,Rinehart Alex R.,Graham Neil M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference17 articles.

1. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

2. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions

3. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

5. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multidisciplinary approach for people with HIV failing antiretroviral therapy in South Africa;Southern African Journal of HIV Medicine;2024-07-22

2. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa;Annals of Internal Medicine;2021-12

3. Determination of serum DNA purity among patients undergoing antiretroviral therapy using NanoDrop-1000 spectrophotometer and polymerase chain reaction;Biomedical and Biotechnology Research Journal (BBRJ);2020

4. The management of treatment-experienced HIV patients (including virologic failure and switches);Therapeutic Advances in Infectious Disease;2020-01

5. Management of Virologic Failure and HIV Drug Resistance;Infectious Disease Clinics of North America;2019-09